Asymmetry Capital Management L.P. bought a new position in shares of Natera Inc (NASDAQ:NTRA) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,458 shares of the medical research company’s stock, valued at approximately $628,000. Natera accounts for approximately 1.0% of Asymmetry Capital Management L.P.’s investment portfolio, making the stock its 22nd largest holding.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Board of Administration of Florida Retirement System increased its stake in shares of Natera by 6.7% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock worth $160,000 after purchasing an additional 717 shares during the period. Legal & General Group Plc increased its stake in shares of Natera by 14.5% during the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares during the period. JGP Global Gestao de Recursos Ltda. increased its stake in shares of Natera by 10.5% during the first quarter. JGP Global Gestao de Recursos Ltda. now owns 13,518 shares of the medical research company’s stock worth $279,000 after purchasing an additional 1,280 shares during the period. Brandywine Managers LLC increased its stake in shares of Natera by 12.9% during the fourth quarter. Brandywine Managers LLC now owns 26,200 shares of the medical research company’s stock worth $366,000 after purchasing an additional 3,000 shares during the period. Finally, Great West Life Assurance Co. Can increased its stake in shares of Natera by 136.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after purchasing an additional 3,420 shares during the period. Institutional investors own 80.32% of the company’s stock.
NTRA has been the topic of a number of recent research reports. BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 20th. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research note on Saturday, February 23rd. Finally, Canaccord Genuity reiterated a “buy” rating and set a $25.00 target price on shares of Natera in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $28.25.
NASDAQ:NTRA traded down $0.67 during trading hours on Tuesday, reaching $24.20. 961,761 shares of the company were exchanged, compared to its average volume of 664,614. The company has a market capitalization of $1.68 billion, a P/E ratio of -11.26 and a beta of 1.41. Natera Inc has a 1-year low of $11.08 and a 1-year high of $29.62. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.73.
Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.05. The business had revenue of $66.82 million for the quarter, compared to the consensus estimate of $66.40 million. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. On average, sell-side analysts anticipate that Natera Inc will post -2.17 EPS for the current fiscal year.
WARNING: “Asymmetry Capital Management L.P. Takes $628,000 Position in Natera Inc (NASDAQ:NTRA)” was reported by Tech Know Bits and is the property of of Tech Know Bits. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://techknowbits.com/2019/06/11/asymmetry-capital-management-l-p-takes-position-in-natera-inc-ntra.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.